Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Dec 2, 2003rhIGF-I/rhIGFBP-3, SomatoKine, Found to Delay the Onset of Type I Diabetes
-
Oct 16, 2003Insmed to Present to Rodman and Renshaw Healthcare Conference; Presentation to be Webcast Live
-
Sep 23, 2003Insmed to Offer Data Showing Efficacy of Drug Candidate in Breast Cancer
-
Sep 15, 2003Insmed's Phase III Drug Candidate to Be Featured in Two Podium Presentations at European Society for Paediatric Endocrinology
-
Jul 31, 2003Insmed Incorporated Reports Improved Financial Results for Second Quarter and First Half of 2003
-
Jul 24, 2003Insmed Incorporated to Webcast Second Quarter Earnings Conference Call; Thursday, July 31, at 11:00 a.m. ET - 10:00 a.m. CT
-
Jul 16, 2003Insmed Inc. Conludes Private Placement Led by Wells Fargo Securities Raising $1.9 Million More Than Previously Reported
-
Jul 14, 2003Insmed Reports Positive Data to AACR with rhIGFBP-3 in Cancer
-
Jul 11, 2003Insmed Inc. Raises $12 Million in Private Placement of Common Stock Lead by Wells Fargo Securities
-
Jul 9, 2003Insmed Incorporated to Present Positive Oncology Data On rhIGFBP-3 at the Annual Meeting of the American Association of Cancer Research
-
Jun 23, 2003Insmed Launches Pivotal Phase III Clinical Trial in GHIS; Data Analysis Planned for Early 2004
-
Jun 20, 2003Insmed Presents Positive Data on Lead Drug Candidate at Endocrine Society Annual Meeting; Study Shows Advantages of Company's rhIGF-I/rhIGFBP-3 In Treating Growth Disorder
-
Jun 20, 2003Insmed Receives European Orphan Drug Designation For rhIGF-I/rhIGFBP-3; Product Will Have 10 Years of Market Exclusivity in Treatment of Growth Disorder
-
Jun 19, 2003Insmed Announces Management Reorganization; Ronald D. Gunn Promoted to Executive VP; Lewis Stuart Departs as VP Commercial Development
-
Jun 18, 2003Insmed to Present Lead Drug Candidate at the Endocrine Society Annual Meeting
-
Jun 17, 2003Insmed Selected to Present to BIO 2003 Business Forum; Presentation to be Webcast Live
-
Jun 12, 2003Insmed to Report Positive Effects of rhIGF-I/rhIGFBP-3 In Adolescent Subjects with Type 1 Diabetes
-
Jun 2, 2003Insmed Presents Data To ASCO Highlighting Potential Benefit Of rhIGFBP-3 in Cancer; rhIGFBP-3 Shown to Enhance Chemotherapy in Models of Human Breast Cancer
-
May 29, 2003Insmed to Present Positive Cancer Data to ASCO
-
May 16, 2003Insmed Incorporated to Present at Techvest European Healthcare Conference
-
May 12, 2003Insmed Regains Full Compliance with Nasdaq National Market System Listing Requirements
-
May 2, 2003Insmed Incorporated Announces Improved Financial Results for First Quarter 2003; Narrowing of Net Loss Exceeds Expectations; Cash Burn Rate Drops Sharply
-
Apr 25, 2003Insmed Incorporated To Webcast First Quarter Earnings Conference Call; Friday, May 2, at 11:00 a.m. ET - 10:00 a.m. CT
-
Apr 11, 2003Insmed Announces Publication of Investment Profile; Full Text Available on Corporate Website
-
Apr 8, 2003Insmed Chairman to Provide Positive Outlook During CEOcast.com's Virtual Healthcare Conference
-
Apr 8, 2003Insmed Initiates Named Patient Programme For rhIGF-I/rhIGFBP-3, An Investigational Drug for Severe Growth Disorders
-
Apr 7, 2003Insmed Announces Improved Performance Expectations for First Quarter; Lead Product Candidate Prepared to Enter Phase III Trials
-
Apr 4, 2003Insmed Reports Positive Data with rhIGFBP-3 in Cancer; rhIGFBP-3 Improves Effect of Standard Cancer Therapies; rhIGFBP-3 Inhibits Tumor Growth up to 70%
-
Apr 2, 2003Insmed CEO to Highlight Near Term Commercial Opportunity; Lead Drug on Track for Potential FDA Approval in 2004; Cash Expected to Fund Operations Through Potential Approval
-
Apr 1, 2003Insmed Chairman And CEO Provides Positive Outlook in Special Letter to Shareholders
-
Mar 28, 2003Insmed Incorporated Retains Investor Relations International As Investor Relations Counsel; Company to Immediately Implement New Shareholder Communications Program
-
Feb 3, 2003Insmed Incorporated Reports Year-End and Fourth Quarter Financial Results
-
Jan 29, 2003Insmed Reports Positive Effects of SomatoKine -rhIGF-I/rhIGFBP-3- In Adolescent Subjects With Type 1 Diabetes
-
Jan 28, 2003Insmed Incorporated to Webcast Fourth Quarter Earnings Conference Call; Tuesday, February 4, at 8:00 a.m. ET - 7:00 a.m. CT
-
Jan 27, 2003Insmed Incorporated Appeals Delisting Notification From Nasdaq
-
Jan 7, 2003Insmed Incorporated Announces Positive Preclinical Oncology Data With rhIGFBP-3
-
Nov 4, 2002Insmed Presents IGFBP-3 Anti-Cancer Data at the International Symposium on the Functional Role of IGFBP's
-
Oct 31, 2002Insmed Incorporated To Webcast Third Quarter Earnings Conference Call; Thursday, October 31, 2002, at 8:30 a.m. ET -7:30 a.m. CT
